July 17, 2017 / 9:17 PM / 4 months ago

U.S. FDA approves Puma Biotech's breast cancer treatment

July 17 (Reuters) - The U.S. Food and Drug Administration (FDA) on Monday approved Puma Biotechnology Inc’s lead drug to treat patients with a type of early-stage breast cancer.

Puma’s drug, neratinib, lowers the risk of the cancer returning following initial treatment, and is the first treatment of its kind, the FDA said in a statement. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sai Sachin Ravikumar)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below